8 results about "Statin therapy" patented technology

Described herein are formulations for the controlled release of statin therapies and methods related thereto.

Described herein are formulations for the controlled release of statin therapies and methods related thereto.

In various embodiments, the present disclosure provides methods of reducing the risk of cardiovascular events in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising from about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Methods of using visual functions such as dark adaptation, low luminance visual acuity, low luminance deficit, contrast sensitivity and scotopic sensitivity as functional biomarkers for statin therapy in AMD. These biomarkers can be used, for example, to support clinical trials of statin therapy for AMD by identifying participants more likely to respond, by providing an early indication of response, or by serving as an endpoint; or to support treatment of AMD patients with statins by identifying patients more likely to respond, by providing an early indication of responders vs. non-responders, or by confirming a treatment benefit.

The present invention provides methods for treating diseases and disorders associated with elevated lipid and lipoprotein levels. These methods consist of administering a pharmaceutical composition containing a PCSK9 inhibitor to a patient at high cardiovascular risk. In certain formulations, the PCSK9 inhibitor is an anti-PCSK9 antibody, such as the example antibody designated mAb316P or alirocumab. The methods of the present invention are useful for treating patients at high cardiovascular risk who have hypercholesterolemia and elevated levels of other atherogenic lipoproteins that are not adequately controlled with the maximum tolerated dose of statins.In particular, the methods of the present invention are useful for reducing cardiovascular risk and decreasing atherogenic lipoproteins in patients with high cardiovascular risk during the 12 months following an acute coronary syndrome event, despite treatment with the maximum tolerated dose of statins.

Disclosed herein are methods for enhancing immune responses to a vaccine in immunocompromised individuals, including those receiving a statin therapy. Related products are also provided.

In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy and having atrial fibrillation and / or flutter by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin.